Manufacturer of Controlled Substances; Notice of Application

---
identifier: "/us/fr/E6-12459"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Manufacturer of Controlled Substances; Notice of Application"
title_number: 0
title_name: "Federal Register"
section_number: "E6-12459"
section_name: "Manufacturer of Controlled Substances; Notice of Application"
positive_law: false
currency: "2006-08-02"
last_updated: "2006-08-02"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Justice Department"
document_number: "E6-12459"
document_type: "notice"
publication_date: "2006-08-02"
agencies:
  - "Justice Department"
  - "Drug Enforcement Administration"
fr_citation: "71 FR 43814"
fr_volume: 71
---


#  Manufacturer of Controlled Substances; Notice of Application

Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on February 19, 2006, Orasure Technologies, Inc., Lehigh University, Seeley G. Mudd-Building 6, Bethlehem, Pennsylvania 18015, made application by renewal, and by letter, to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedule I and II:

| Drug | Schedule |
| --- | --- |
| Lysergic acid diethylamide (LSD) (7315) | I |
| 4-Methoxyamphetamine (7411) | I |
| Normorphine (9313) | I |
| Tetrahydrocannabinols (THC) (7370) | I |
| Alphamethadol (9605) | I |
| Amphetamine (1100) | II |
| Methamphetamine (1105) | II |
| Cocaine (9041) | II |
| Hydromorphone (9150) | II |
| Benzoylecgonine (9180) | II |
| Hydrocodone (9193) | II |
| Morphine (9300) | II |
| Oxycodone (9143) | II |
| Meperidine (9230) | II |
| Methadone (9250) | II |
| Oxymorphone (9652) | II |

The company plans to manufacture the listed controlled substances in bulk to manufacture controlled substance derivatives. These derivatives will be used in diagnostic products created specifically for internal use only.

Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR § 1301.33(a).

Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC. 20537, Attention: DEA *Federal Register* Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA *Federal Register* Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than October 2, 2006.

Dated: July 26, 2006.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.